<DOC>
	<DOC>NCT01193179</DOC>
	<brief_summary>The purpose of this study is to investigate the safety of OPC-262 administered orally in combination with another oral antihyperglycemic agent</brief_summary>
	<brief_title>A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1) Patients who are capable of giving informed consent 2) Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>